Chemotherapy with gemcitabine for unresectable intrahepatic cholangiocarcinoma in a patient undergoing maintenance hemodialysis.
Gemcitabine
Hemodialysis
Intrahepatic cholangiocarcinoma
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
31
05
2021
accepted:
05
07
2021
pubmed:
10
7
2021
medline:
16
9
2021
entrez:
9
7
2021
Statut:
ppublish
Résumé
A 56-year-old man with chronic renal failure due to diabetic nephropathy had received maintenance dialysis (every 4 h, three times/week). A hypoechoic tumor measuring 67 × 50 mm in the right lobe of the liver was discovered following routine abdominal ultrasonography. Dynamic computed tomography showed a low-density liver tumor, enlarged hilar lymph node, and a small nodule on the dorsal side of the lower lobe of the left lung. Histopathological examination of the liver tumor revealed intrahepatic cholangiocarcinoma. We developed a chemotherapy treatment plan with gemcitabine, which can be performed concurrently with hemodialysis. Gemcitabine (1000 mg/m
Identifiants
pubmed: 34241805
doi: 10.1007/s12328-021-01478-4
pii: 10.1007/s12328-021-01478-4
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1511-1516Informations de copyright
© 2021. Japanese Society of Gastroenterology.
Références
Nitta K, Goto S, Masakane I, et al. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther. 2020;6:41.
doi: 10.1186/s41100-020-00286-9
Kaizu K. Prevalence of malignancies in digestive organs of dialysis patients: diseases of alimentary Tract in Maintenance Dialysis Patients. Jpn J Clin Dial. 2006;22:1123–9.
Chien CC, Han MM, Chiu YH, et al. Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer. 2017;8:9–18.
doi: 10.7150/jca.16550
Nagino M, Hirano S, Yoshitomi H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28:26–54.
doi: 10.1002/jhbp.870
Kiani A, Köhne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol. 2003;51:266–70.
doi: 10.1007/s00280-003-0574-3
Yoshida M, Ukaji M, Saisho H. Successful management for unresectable pancreatic cancer with chronic liver failure treated by gemcitabine and hemodialysis. Suizo. 2012;27:199–205.
doi: 10.2958/suizo.27.199
Chang PY, Dai MS, Ho CL, et al. Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis. J BUON. 2013;18:1058–61.
pubmed: 24344039
Takakura K, Koido S, Takahara A, et al. Long-term management of gemcitabine in a patient with advanced pancreatic cancer undergoing haemodialysis. J Chemother. 2014;26:369–72.
doi: 10.1179/1973947813Y.0000000150
Okazaki M, Tajima H, Ohbatake Y, et al. A Case of pathological complete response induced by preoperative chemotherapy with gemcitabine plus nab-paclitaxel in a patient with pancreatic cancer on hemodialysis. Gan To Kagaku Ryoho. 2018;45:2162–4.
pubmed: 30692318
Kaneko T, Sugimori K, Tozuka Y, et al. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Clin J Gastroenterol. 2019;12:484489–99.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
doi: 10.1056/NEJMoa0908721
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. Br J Cancer. 2010;103:469–74.
doi: 10.1038/sj.bjc.6605779
Masumori N, Kunishima Y, Hirobe M, et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol. 2008;38:182–5.
doi: 10.1093/jjco/hym171